A Dual Disease State TAVR SolutionJenaValve is a clinical-stage medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of both severe aortic regurgitation and stenosis. JenaValve is passionate about providing our physician partners with cutting edge technology aimed at improving the lives of our patients. […]
Location: Germany
Employees: 11-50
Total raised: $212.5M
Investors 3
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
| - | Andera Par... | anderapart... |
| 16.06.2022 | GIMV | gimv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 31.08.2022 | - | $100M | - |
| 05.02.2020 | - | $50M | - |
| 23.07.2013 | - | $62.5M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 31.08.2022 | JenaValve Raises $100 Million to Advance Trilogy TAVR Soluti... | JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiat... | neomed.net... |
| 05.02.2020 | JenaValve Technology Closes $50 Million Financing | JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Ao... | neomed.net... |
| 23.07.2013 | JenaValve raises $62.5 Million in Venture Funding - Capital ... | JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of... | neomed.net... |
| 24.09.2007 | Life sciences briefing: Monday, Sept. 24, 2007 | Featured companies: Adnexus Therapeutics, Bristol-Myers Squibb, Cellerix, Elixir Therapeutics, Genom... | venturebea... |